This week's View covers key points to remember from a comparison of the US and European guidelines for the diagnosis and management of syncope; the incorporation of cardiac magnetic resonance, genetic, and biomarker data to enable identification of distinct subgroups within the Hypertrophic Cardiomyopathy Registry; and differences in outcome by primary antihypertensive agents among the first-line drug classes.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Adenosine, Aneurysm, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Arrhythmias, Cardiac, Atrial Fibrillation, Biomarkers, Body Mass Index, Bradycardia, Calcium Channel Blockers, Cardiomyopathy, Hypertrophic, Coronary Artery Disease, Diagnostic Imaging, Dihydropyridines, Diuretics, Echocardiography, Electrophysiology, Evidence-Based Medicine, Exercise Test, Gadolinium, Genetic Testing, Heart Failure, Hypertension, Hypertrophy, Hypotension, Orthostatic, Magnetic Resonance Spectroscopy, Mutation, Myocardial Infarction, Myocardial Ischemia, Natriuretic Peptide, Brain, Peptide Fragments, Peptidyl-Dipeptidase A, Primary Prevention, Reflex, Syncope, Risk Factors, Sarcomeres, Stroke, Syncope, Syncope, Vasovagal, Tachycardia, Ventricular, Thiazides, Troponin T, Anticoagulants

< Back to Listings